Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have received a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $78.00.

Several brokerages have recently weighed in on VERA. The Goldman Sachs Group reiterated a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd. HC Wainwright upped their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research note on Wednesday, March 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd.

Vera Therapeutics Stock Performance

Shares of VERA opened at $31.81 on Friday. The firm’s fifty day simple moving average is $37.40 and its two-hundred day simple moving average is $41.37. Vera Therapeutics has a 12 month low of $19.07 and a 12 month high of $56.05. The stock has a market capitalization of $2.28 billion, a P/E ratio of -5.74 and a beta of 0.93. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the business posted ($0.81) EPS. As a group, analysts predict that Vera Therapeutics will post -6.23 EPS for the current year.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 22,951 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at approximately $10,362,498.20. This trade represents a 8.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its holdings in Vera Therapeutics by 49.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after buying an additional 1,795,537 shares during the period. Deerfield Management Company L.P. boosted its holdings in Vera Therapeutics by 8.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after buying an additional 293,040 shares during the period. Vanguard Group Inc. boosted its holdings in Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after buying an additional 379,748 shares during the period. Vestal Point Capital LP boosted its holdings in Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after buying an additional 600,000 shares during the period. Finally, Eversept Partners LP boosted its holdings in Vera Therapeutics by 9.4% in the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after buying an additional 264,468 shares during the period. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.